Urgent.News

What's breaking now, across thousands of outlets.

More in Finance & Markets

Is AbbVie a Buy After Its Latest Earnings Report?

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

  • AbbVie's Q3 revenue up 10.3% to $17.4 billion
  • Skyrizi and Rinvoq drive 48.7% of total revenue
  • AbbVie raises full-year adjusted EPS guidance and dividend

More from Saturday 31 October →